Baykan Emine Kartal, Erdoğan Mehmet, Özen Samim, Darcan Şükran, Saygılı L Füsun
Ege University Faculty of Medicine, İnternal Medicine Department of Endocrinology and Metabolism Unit, İzmir, Turkey.
J Clin Res Pediatr Endocrinol. 2013;5(2):129-32. doi: 10.4274/Jcrpe.970.
Aromatase deficiency (AD) is a rare autosomal recessive inheritance syndrome. Its worldwide incidence is unknown, and there are few case reports in the literature. Aromatase dysfunction develops due to CYP19A1 gene mutation and a decrease in estrogen synthesis. Estrogen deficiency can induce delayed epiphyseal closure, eunuchoid body habitus, osteopenia, and osteoporosis in both genders. Our patient was a 27-year-old male who presented with bone pain, recurrent bone fractures associated with minimal trauma starting in puberty, and a progressive increase in height. Laboratory tests revealed that the blood levels of follicle-stimulating hormone and luteinizing hormone were above normal, testosterone level was normal, and estrogen was undetectable. Plain bone radiography of the left wrist and hand demonstrated that the epiphyses were still unfused. Lumbar osteoporosis was detected in bone densitometry. In the genetic analysis, homozygous R375H guanine-adenine (G-A) mutation was detected in the CYP19A1 gene, and a diagnosis of AD was reached. Treatment with 25 μg transdermal estradiol was started. All family members were examined. Homozygous R375H G-A mutation was detected in the patient's younger brother. Heterozygous R375H G-A mutation was found in his mother, father, and older brother. In conclusion, this AD patient requires lifetime estrogen replacement in order to provide sufficient bone mineralization, to reduce the risk of bone fractures, and to lead a healthy life. The best method to prevent the possible complications is to diagnose the AD syndrome at early ages and to provide adequate estrogen replacement starting at puberty.
芳香化酶缺乏症(AD)是一种罕见的常染色体隐性遗传综合征。其全球发病率尚不清楚,文献中仅有少数病例报告。由于CYP19A1基因突变和雌激素合成减少,导致芳香化酶功能障碍。雌激素缺乏可导致男女骨骺闭合延迟、类无睾体型、骨质减少和骨质疏松。我们的患者是一名27岁男性,自青春期起出现骨痛、与轻微创伤相关的反复骨折以及身高逐渐增加。实验室检查显示,促卵泡生成素和黄体生成素的血液水平高于正常,睾酮水平正常,未检测到雌激素。左手腕和手部的普通骨X线片显示骨骺仍未融合。骨密度测定检测到腰椎骨质疏松。在基因分析中,在CYP19A1基因中检测到纯合的R375H鸟嘌呤 - 腺嘌呤(G - A)突变,从而得出AD的诊断。开始使用25μg经皮雌二醇进行治疗。对所有家庭成员进行了检查。在患者的弟弟中检测到纯合的R375H G - A突变。在他的母亲、父亲和哥哥中发现杂合的R375H G - A突变。总之,这位AD患者需要终身雌激素替代治疗,以提供足够的骨矿化,降低骨折风险,并过上健康的生活。预防可能并发症的最佳方法是在早年诊断AD综合征,并从青春期开始提供充足的雌激素替代治疗。